Chroma signs huge deal with GSK


Abingdon/London – Biotech platform technologies apparently still matter. An advanced technology platform could now end up bringing US$1bn to British drug developer Chroma Therapeutics Ltd. At the end of June, the Abingdon-based biotech company inked a collaboration agreement with pharma giant GlaxoSmithKline (GSK) to develop macrophage-targeted compounds using Chroma’s esterase-sensitive motif (ESM) technology. The technology is designed to target compounds in the cytoplasm of specific cells by coupling them to certain amino acid esters that are cleaved inside the cell, leaving a charged molecule incapable of leaking out of the cell. The approach could bring advantages in treatments for inflammatory diseases by increasing the therapeutic window when compared to the “parent” drug, and reducing systemic exposure outside of the macrophages. Chroma has already applied the technology to a number of key inflammation targets such as P38 MAP Kinase, PI-3 Kinase, IKK-beta and PDE4.
Under the terms of the collaboration with GSK’s Centre of Excellence for External Drug Discovery (CEEDD) in Stevenage (UK), Chroma will undertake four programmes to identify small molecule therapeutics, including a macrophage-targeted HDAC inhibitor programme for inflammatory disorders such as RA.
GSK announced that Chroma will receive a significant up-front cash payment, and that GSK will participate in Chroma’s recent EUR17.5m equity financing. Additionally, Chroma is to receive milestones, option fees and tiered royalties based on compounds arising from the collaboration. The deal could total up to US$1bn in case of clinical proof-of-concept in all programmes.
GSK may elect to obtain an exclusive, worldwide license to product candidates within the programme. At such time GSK will assume full responsibility for development and commercialisation. Chroma will retain full rights to further develop and commercialise its product candidates in any programme GSK chooses not to license.
“We believe Chroma’s ESM platform has tremendous potential,” stated Shelagh Wilson, Vice President and Head of the European CEEDD, while Chroma’s CEO Ian Nicholson said the collaboration was a strong validation of his company’s cell accumulation approach.



London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...



Surrey – The UK government is investing an additional £80m (€93.5m) to fund continued development of the Institute for Animal Health (IAH) at Pirbright, an institute of the Biotechnology and Biological Sciences Research Council...



Rijeka/London – Allergies like asthma or psoriasis might arise from environmental toxins, suggest researchers from Rijeka University (Croatia) and King’s College (London). In mice, they identified a special population of T cells...



London – Interesting times ahead in the European cancer treatment market. A report states that in the UK alone, diagnosis and treatment costs are likely to increase by 62%, from £9.4 billion in 2010 to £15.3 billion by 2021. The...



York - Tissue Regenix Group plc plans to raise €29m through the sale of 181.8 million shares. The regenerative medical device company is held within the IP Group portfolio and a spin-out company from the University of Leeds. The...



London – Cancer Research UK has begun recruiting patients in the first phase of its Stratified Medicine Programme, which is aimed at finding cancer biomarkers and establishing a genetic testing service in the UK. The charity’s...



London – British Prime Minister David Cameron is trying to come to the rescue of Britain’s embattled biopharmaceutical industry. He has earmarked €210m to support a “biomedical catalyst fund” to back early-stage academic and...



London - David Cameron plans to come to the rescue of Britain's embattled biopharmaceutical industry. The conservative prime minister has earmarked £180m (€210 million) to support a "biomedical catalyst fund" to back ...



Cancer Research UK has started recruiting patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The charity's multi-million...

Displaying results 11 to 20 out of 396

< Previous 11-20 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • BASILEA133.60 CHF4.70%
  • WILEX4.21 EUR3.69%


  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%


  • 4SC4.65 EUR263.3%
  • SYNGENTA422.00 CHF29.1%
  • WILEX4.21 EUR23.8%


  • CYTOS0.63 CHF-42.7%
  • MEDIGENE8.58 EUR-32.4%
  • BIOTEST76.00 EUR-22.8%


  • WILEX4.21 EUR419.8%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%


  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 22.05.2015

Current issue

All issues